ColinJohnMeyerMDMBA

Other MD/DO • Plano, TX

Chief Research and Development Officer, Reata Pharmaceuticals, Inc.

Join to view full profile

Dr. Meyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Meyer's full profile

Already have an account?

Office
Reata Pharmaceuticals, Inc.
5320 Legacy Drive Plano
Plano, TX 75024
Phone+1 972-865-2200

Education & Training

University of Texas Southwestern Medical SchoolClass of 2003

Clinical Trials

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction Start of enrollment: 2007 Apr 30
Terminated
Phase 1, Phase 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2011 Jun 30
Terminated
Phase 3
A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl Start of enrollment: 2011 Oct 31
Completed
Phase 1
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects Start of enrollment: 2011 Dec 01
Completed
Phase 1
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2012 Apr 30
Terminated
Phase 1
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2012 Apr 30
Withdrawn
Phase 1
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function Start of enrollment: 2012 Apr 30
Completed
Phase 1
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis Start of enrollment: 2012 Jul 31
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

99 citations
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
David A. Lynch, Jennifer M. Farmer, Lauren A. Hauser, Ian A. Blair, Qing Qing Wang
Annals of Clinical and Translational Neurology. 2019-01-01
68 citations
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
Mohammad A. Aminzadeh, Scott A. Reisman, Nosratola D. Vaziri, Mahyar Khazaeli, Jun Yuan
Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 2014-05-09
94 citations
Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes
Tomonaga Ichikawa, Jinqing Li, Colin J. Meyer, Joseph S. Janicki, Mark Hannink
Plos One. 2009-12-21

Press Mentions

Bob Goeltz Bolts Unity Biotechnology to Become CFO at Arcus Biosciences; John Johnson Tapped for His Latest CEO GigJuly 10th, 2020
Bardoxolone Methyl Improved Kidney Function in Patients with Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix StudyMay 25th, 2018

ColinJohnMeyerMDMBA

Dr. Meyer is on Doximity

Education & Training

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.